Request Consultation

IV Ketamine Therapy & Clinical Innovation

Table of Contents

Information alone doesn’t heal—understanding does. At Brain Spa, we translate leading clinical research into clear, empowering knowledge so you can take control of your psychological wellness journey.
Request Consultation

Why Choose BrainSpa.org

Beyond Generic Health Information

1

1-on-1 Dedicated Clinician Presence

Many clinics leave patients alone in dark rooms with a call button. Brain Spa provides dedicated, continuous clinician presence throughout your IV infusion for maximum safety and emotional grounding.

2

Gold-Standard Evidence Base

We focus on Intravenous (IV) Ketamine because randomized controlled trials consistently demonstrate it has the highest bioavailability and most robust evidence base across all administration routes.

3

Integrative Neural Plasticity

Biochemical interventions are most effective when paired with mindful integration, clinical psychotherapy, and a tranquil, non-institutional environment designed for total sensory comfort.

Administration Route Comparison

Why Intravenous (IV) Ketamine is Our Focus

Not all routes of ketamine administration produce equal results. Clinical evidence proves that the delivery method dictates therapeutic strength and bioavailability.

Gold Standard

IV Ketamine Infusion

100% Bioavailability
  • ✓ Strongest scientific evidence base supported by multiple RCTs.
  • ✓ Precise real-time dose control and instant biological delivery.
  • ✓ Continuously monitored 1-on-1 by medical staff.

Intramuscular (IM)

~93% Bioavailability

Emerging clinical data with potential, but offers limited control over absorption rate once injected.

Oral Ketamine

< 20% Bioavailability

Weakest scientific evidence base due to extensive first-pass liver metabolism and inconsistent absorption.

Source: ACP Journals / Annals of Internal Medicine (2023)

Clinical Data Summary

Ketamine Science & Mental Health Evidence

Neurobiology Paradigm Shift

How Ketamine Enhances Synaptic Plasticity

Traditional antidepressants attempt to increase monoamine neurotransmitters (like serotonin) over weeks or months. Ketamine represents a fundamental paradigm shift by targeting the glutamatergic system for rapid antidepressant response.

The Glutamatergic Synaptic Plasticity Pathway:

  1. 1. NMDA Blockade: Ketamine acts primarily as an NMDA receptor antagonist on inhibitory GABAergic neurons.
  2. 2. Glutamate Surge: This blockade triggers a surge of glutamate that activates AMPA receptors.
  3. 3. BDNF & mTOR Signaling: AMPA activation increases Brain-Derived Neurotrophic Factor (BDNF) expression and stimulates the mTOR pathway.
  4. 4. Synaptic Plasticity: Enhances synaptic connections and restores damaged neural circuits.
Medical Definition

Treatment-Resistant Depression (TRD)

According to an invited review in the New England Journal of Medicine, TRD is defined as a lack of response to two or more adequate antidepressant trials within a single depressive episode.

"An adequate trial is generally considered a therapeutic dose for at least 8 weeks."

Both IV racemic ketamine (off-label with robust clinical evidence) and intranasal esketamine (Spravato, FDA-approved) demonstrate rapid reduction of depressive and suicidal symptoms.

Landmark Trial: NEJM 2023

ELEKT-D Trial: IV Ketamine vs. ECT

The ELEKT-D trial (N=403) demonstrated that IV ketamine was noninferior to Electroconvulsive Therapy (ECT) for nonpsychotic Treatment-Resistant Depression.

55.4% IV Ketamine Response
41.2% ECT Response

Point estimates numerically favored IV ketamine by 14.2 percentage points (95% CI 3.9–24.2; P < 0.001 for noninferiority).

Trauma & Clinical Data

IV Ketamine for PTSD Symptom Reduction

PTSD is a psychiatric condition developing after trauma exposure, defined by four core symptom clusters: intrusion, avoidance, negative cognition/mood alterations, and hyperarousal lasting over one month.

Epidemiology & Veterans

US lifetime prevalence is 6.1% (4.7% 12-month). Global prevalence is ~3.9–6%. Among military veterans, prevalence reaches 13–30% depending on combat exposure.

Trauma Exposure vs Diagnosis

Exposure to trauma is common, but most individuals do not develop PTSD. Fewer than 10% of trauma-exposed individuals meet full clinical criteria.

IV Ketamine vs Nasal Esketamine

A veteran case series (N=15) with TRD & PTSD showed IV racemic ketamine achieved greater symptom reduction in both depression (PHQ-9: -5.6 vs -2.4) and PTSD (PCL-5: -11.8 vs -4.3) compared to prior nasal esketamine.

Peer-Reviewed References

Academic studies, clinical trials, and professional guidelines supporting BrainSpa.org content.

  1. ACP Journals / Annals of Internal Medicine. (2023). Efficacy and Safety of Ketamine Administration Routes for PTSD and Major Depression. View Study
  2. American Psychological Association (APA). (2017). Clinical Practice Guideline for the Treatment of Posttraumatic Stress Disorder (PTSD) in Adults. View Guidelines (PDF)
  3. McIntyre, R. S., Alsuwaidan, M., Baune, B. T., et al. (2023). Treatment-Resistant Depression: Definition, Prevalence, Detection, Management, and Investigational Interventions. World Psychiatry, 22(3), 394–412. DOI: 10.1002/wps.21120
  4. Shim, S. R., Jeong, H. S., Bommersbach, T. J., et al. (2026). Ketamine Infusions and Rapid Reduction of Suicidal and Depressive Symptoms in Major Depressive Episode. JAMA Psychiatry. JAMA Network
  5. Duman, R. S., & Aghajanian, G. K. (2012). Synaptic dysfunction in depression: Potential therapeutic targets (NMDA antagonism, BDNF expression, and mTOR signaling). Science, 338(6103), 68–72. DOI: 10.1126/science.1222939
  6. Zarate, C. A., Jr., Singh, J. B., Carlson, P. J., et al. (2006). A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Archives of General Psychiatry, 63(8), 856–864. DOI: 10.1001/archpsyc.63.8.856
  7. Anand, A., Mathew, S. J., Sanacora, G., et al. (2023). Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression (ELEKT-D Trial). The New England Journal of Medicine, 388(25), 2315–2325. NEJM Article
  8. American Psychiatric Association. (2022). Diagnostic and Statistical Manual of Mental Disorders (5th ed., text rev.; DSM-5-TR). Posttraumatic Stress Disorder Diagnostic Criteria & Symptom Clusters. PsychiatryOnline
  9. Koenen, K. C., Ratanatharathorn, A., Ng, L., et al. (2017). Posttraumatic stress disorder in the World Mental Health Surveys. Psychological Medicine, 47(13), 2260–2274. DOI: 10.1017/S0033291717000708
  10. Feder, A., Parides, M. K., Murrough, J. W., et al. (2014). Efficacy of Intravenous Ketamine for Treatment of Chronic Posttraumatic Stress Disorder. JAMA Psychiatry, 71(6), 681–688. DOI: 10.1001/jamapsychiatry.2014.62

Connect With Brain Spa

Have questions about IV ketamine infusion protocols or clinical eligibility? Contact our medical team for a confidential inquiry.

FAQ

IV administration has close to 100% bioavailability, compared to roughly 93% for intramuscular and under 20% for oral. It also lets the clinical team control the dose in real time during the infusion, which isn’t possible with oral or IM delivery.
It’s most studied for treatment-resistant depression (TRD) and PTSD, with clinical trial data showing meaningful symptom reduction in both. Some clinics also use it for anxiety when paired with psychotherapy.
You’re seated or reclined comfortably while the infusion is administered over roughly 40 minutes, with a dedicated clinician present throughout to monitor your response and support you. Most people rest quietly afterward before being cleared to head home.
Treatment plans are individualized based on your diagnosis, history, and response to earlier sessions. A care coordinator will walk you through a recommended course after your intake consultation.
Ketamine has a long track record of safe use in clinical settings when administered by trained medical staff with continuous monitoring. As with any medical treatment, it isn’t right for everyone — your care team will review your health history to determine if you’re a good candidate.
Spravato is an FDA-approved intranasal esketamine formulation, while IV racemic ketamine is used off-label but supported by a larger, longer-standing body of clinical evidence. Some clinical comparisons have found IV ketamine produces greater symptom reduction than intranasal esketamine in patients who’ve tried both.

Schedule A Free Consultation

Skip to content